Tag: Food and Drug Administration; EMA
Takeda launches drug for treating hereditary angioedema patients in India
CINRYZE™ is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE